BRPI0718609A8 - Anticorpos modificadores de doença cancerosa. - Google Patents

Anticorpos modificadores de doença cancerosa.

Info

Publication number
BRPI0718609A8
BRPI0718609A8 BRPI0718609A BRPI0718609A BRPI0718609A8 BR PI0718609 A8 BRPI0718609 A8 BR PI0718609A8 BR PI0718609 A BRPI0718609 A BR PI0718609A BR PI0718609 A BRPI0718609 A BR PI0718609A BR PI0718609 A8 BRPI0718609 A8 BR PI0718609A8
Authority
BR
Brazil
Prior art keywords
cancer
antibodies
modifying antibodies
disease modifying
cancer disease
Prior art date
Application number
BRPI0718609A
Other languages
English (en)
Inventor
S F Young David
P Findlay Helen
E Hahn Susan
M Cechetto Lisa
Original Assignee
Arius Res Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Res Inc, Hoffmann La Roche filed Critical Arius Res Inc
Publication of BRPI0718609A2 publication Critical patent/BRPI0718609A2/pt
Publication of BRPI0718609A8 publication Critical patent/BRPI0718609A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS MODIFICADORES DE DOENÇA CANCEROSA. A presente invenção refere-se a um método para a produção de anticorpos modificadores de doença cancerosa usando um novo paradigma de triagem. Pela segregação dos anticorpos anticâncer usando-se citotoxicidade para células cancerosas como um ponto final, o processo torna possivel a produção de anticorpos anticâncer para finalidades terapêuticas e diagnósticas. Os anticorpos podem ser usados como auxílio na classificação do estágio e diagnóstico de um câncer e podem ser usados para tratar tumores primários e metástases tumorais. Os anticorpos anticâncer podem ser conjugados a toxinas, enzimas, compostos radioativos e células hematogênicas
BRPI0718609A 2006-11-13 2007-11-13 Anticorpos modificadores de doença cancerosa. BRPI0718609A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86547406P 2006-11-13 2006-11-13
PCT/CA2007/002029 WO2008058381A1 (en) 2006-11-13 2007-11-13 Cancerous disease modifying antibodies

Publications (2)

Publication Number Publication Date
BRPI0718609A2 BRPI0718609A2 (pt) 2015-06-30
BRPI0718609A8 true BRPI0718609A8 (pt) 2015-09-29

Family

ID=39401276

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718609A BRPI0718609A8 (pt) 2006-11-13 2007-11-13 Anticorpos modificadores de doença cancerosa.

Country Status (12)

Country Link
US (1) US20080131365A1 (pt)
EP (1) EP2092058A1 (pt)
JP (1) JP2010509246A (pt)
KR (1) KR20090101885A (pt)
CN (1) CN101535470A (pt)
AU (1) AU2007321665A1 (pt)
BR (1) BRPI0718609A8 (pt)
CA (1) CA2668503A1 (pt)
IL (1) IL198316A0 (pt)
NO (1) NO20091458L (pt)
WO (1) WO2008058381A1 (pt)
ZA (1) ZA200903281B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
AU613590B2 (en) * 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
EP0539970B1 (en) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
ATE244888T1 (de) * 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
ES2150573T3 (es) * 1994-06-24 2000-12-01 Vladimir P Torchilin Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
EP2092058A1 (en) 2009-08-26
CN101535470A (zh) 2009-09-16
CA2668503A1 (en) 2008-05-22
US20080131365A1 (en) 2008-06-05
WO2008058381A1 (en) 2008-05-22
BRPI0718609A2 (pt) 2015-06-30
KR20090101885A (ko) 2009-09-29
IL198316A0 (en) 2011-08-01
NO20091458L (no) 2009-07-31
AU2007321665A1 (en) 2008-05-22
JP2010509246A (ja) 2010-03-25
ZA200903281B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
DK1718737T3 (da) Cancerøs sygdomsmodificerende antistoffer
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
BRPI0512040A (pt) composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2004065422A3 (en) Cancerous disease modifying antibodies
WO2006044486A3 (en) Methods and compositions for the utilization and targeting of osteomimicry
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AR115288A1 (es) Anticuerpos humanizados contra el psma
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
MX2009009533A (es) Conjugados de hidroxipolimero modificado con efecto letal en celulas tumorales.
WO2011045352A3 (en) Spleen tyrosine kinase and brain cancers
BR112014005786A2 (pt) antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
ATE483028T1 (de) Antikörper, die krebserkrankungen modifizieren
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
WO2008058380A8 (en) Cancerous disease modifying antibodies
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
WO2010028820A3 (en) Peripheral zone tumor cells, methods for their preparation and use

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: F. HOFFMANN-LA ROCHE AG (CH)

B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO INPI/RJ NO 020100090488 DE 27/09/2010.

B25C Requirement related to requested transfer of rights

Owner name: F. HOFFMANN-LA ROCHE AG (CH)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020090111090 DE 27/11/2009, E NECESSARIO O DOCUMENTO DE LEGALIZACAO CONSULAR.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: F. HOFFMANN-LA ROCHE AG (CH)

Free format text: ANULADA A EXIGENCIA PUBLICADA NA RPI NO 2342, DE 24/11/2015, UMA VEZ QUE A TRANSFERENCIA CONTIDA NA PETICAO NO 20090111090, DE 27/11/2009, HAVIA SIDO DEFERIDA NA RPI NO 2334, DE 29/09/2015.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.01), A61K 4